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Abstract 
Emerging evidence suggests that the tumor microenvironment plays a critical role in regulating cancer 
stem cells (CSCs) and tumor progression through both autocrine and paracrine signaling.  Elevated 
production of bone morphogenetic proteins (BMPs) from human ovarian cancer cells and stroma has 
been shown to increase CSC proliferation and tumor growth.  Here, we report that Lin28, a stem cell 
factor, binds to BMP4 mRNA in epithelial ovarian carcinoma cells thereby promoting BMP4 expression 
at the posttranscriptional level.  As co-expression of Lin28 and Oct4 (another stem cell factor) has been 
implicated in ovarian cancer CSCs, we also determined that high levels of Lin28 are associated with an 
unfavorable prognosis when co-expressed with high levels of Oct4.  Together, these findings uncover a 
new level of regulation of BMP4 expression, and imply a novel Lin28/Oct4/BMP4-mediated mechanism 
of regulating ovarian tumor cell growth, thus holding potential for the development of new strategies for 
the diagnosis and treatment of ovarian cancer.  
 
Introduction  
Cancer stem cells (CSCs), by definition, have the ability to give rise to both more CSCs (by self-
renewal) and daughter cells of other types (by differentiation); as a result these cells have the capacity to 
regenerate tumor cells.  CSCs have been suggested to contribute to tumor recurrence, metastasis and the 
development of drug-resistance 
1-4.  A recent series of paradigm-shifting studies suggests that cancer 
cells are highly plastic, and under certain conditions, can transition between cell types.  For instance, 
differentiated non-CSCs can revert to CSCs, or vice versa – consistent with the view that the tumor 
microenvironment can reprogram any differentiated cell type into a CSC 
5-10.  While such studies 
demonstrate the critical role of the tumor microenvironment in the development of the CSC phenotype, 
the factor(s) that give rise to this phenotype have not yet been identified. 
  The bone morphogenetic protein (BMP) family is under investigation as one potential family of 
growth factors controlling the growth of CSCs.  BMPs belong to the transforming growth factor-β 
(TGF-β) family of secretory peptides that regulate diverse cellular processes, including proliferation, 
differentiation, migration, adhesion and apoptosis (reviewed in 
11).  BMP-mediated signal-transduction 
pathways play crucial roles in normal tissue development, maintaining tissue homeostasis, and 
tumorigenesis 
12.  Approximately 20 BMP-related proteins have been identified; BMP2 and BMP4 are 
the best-studied members of this family.  In particular, BMP2 and BMP4 are 91% identical at the protein 
level, bind to the same receptors, and likely function interchangeably (reviewed in 
12,13).  Evidence that 
BMP2/4 plays critical roles in regulating ovarian CSCs comes from a recent study demonstrating that 
ovarian cancer-associated mesenchymal stem cells (CA-MSCs) exhibit elevated expression of both 
BMP2 and BMP4.  Treatment of primary ovarian cancer cells or derived cell lines with exogenous 
BMP2 significantly stimulates proliferation of ovarian CSCs in vitro and tumor growth in vivo 
7.  
Further, inhibition of BMP2/4 by Noggin, an extracellular BMP inhibitor, results in partial abrogation of 
CA-MSC promoted tumor growth in mice 
7.    
  In addition to BMPs, specific stem cell factors such as Lin28 and Oct4 may contribute to  
 
regulating ovarian CSCs and tumor progression 
14.  Lin28 and Oct4 are co-expressed highly in 
undifferentiated human embryonic stem (ES) cells but not in most normal adult tissue cells, although 
aberrant activation of expression has been detected in diverse human malignancies (reviewed in 
15,16).  
Oct4 is a transcription factor that regulates expression of a network of genes essential for maintaining 
stem cell pluripotency 
17.  Lin28 is an RNA-binding protein that functions to maintain stem cell viability 
and pluripotency through both blocking the biogenesis of let-7 family of miRNAs and promoting 
translation of mRNAs involved in cell growth and metabolism (reviewed in 
15,16).  Further, Lin28 
regulates Oct4 at the posttranscriptional level: in both human ES and EC (embryonic carcinoma) cells 
Lin28 specifically binds to Oct4 mRNA via recognition of a sequence element in the mRNA and 
stimulates its translation 
18.  Intriguingly, co-expression of Lin28 and Oct4 also has been found in a sub-
population of human epithelial ovarian carcinoma (EOC) cells and has been implicated in CSC function 
14.  Importantly, reducing expression of both Lin28 and Oct4 simultaneously by siRNA-mediated gene 
silencing resulted in synergistic inhibition of cell growth and induction of apoptosis in EOC-derived cell 
lines 
14.  However, the clinical impact of this co-expression is not known, despite the fact that this sub-
population has been associated with high tumor grade in a 14-patient cohort 
14.  
  In this study, we identify BMP4 mRNA as a novel target of Lin28 regulation at the post-
transcriptional level, revealing a new layer of complexity in regulation of BMP4 expression.  We also 
demonstrate that co-expression of Lin28 and Oct4 negatively impacts patient survival.  Together, these 
results imply Lin28-mediated BMP4 activation in the poor prognosis observed in a sub-population of 
ovarian cancer patients expressing high levels of both Lin28 and Oct4. 
 
Results  
Lin28 associates with BMP4 mRNA in tumor cells 
Our recent studies on the expression of Lin28 and Oct4 in ovarian cancer suggested that these gene 
products might be involved in regulating factors that modulate the tumor microenvironment in epithelial  
 
ovarian cancer (EOC).  The identification of BMP2/4 as potent drivers of ovarian CSC growth and 
tumor progression 
7 suggested to us that there might be a mechanistic link between Lin28 and BMP4.  
  As an RNA-binding protein, Lin28 is known to execute its function through binding to target 
RNAs in a form of ribonucleoprotein particles (RNPs) (reviewed in 
15).  In previous studies we isolated 
Lin28-containing RNPs from human ES cells by immunoprecipitation (IP) using antibodies specific for 
Lin28, followed by identification of associated mRNAs using high throughput deep sequencing.  We 
found approximately 5% of cellular mRNAs to be enriched greater than 2.5-fold (a threshold that 
defines a gene as a putative target of Lin28) in Lin28 IP versus control IP (preimmune serum) 
19. 
Importantly, a subset of mRNAs including those for HMGA1 and RPS13 (ribosomal protein S13) were 
subsequently validated to be Lin28 targets of regulation at the translational level 
19,20.  Retrospective 
scrutiny of these genome-wide data suggested that BMP4 mRNA also was specifically enriched in the 
Lin28 IP fraction, and therefore warranted further investigation.  
  Figure 1A is a screenshot of normalized UCSF Genome Browser alignments of Lin28 IP and 
preimmune IP sequences, demonstrating a 3.9-fold enrichment of BMP4 mRNA in Lin28-containing 
RNPs in human ES cells
 19.  To determine whether BMP4 mRNA also is bound by Lin28 in tumor cells, 
IP experiments were carried out using human ovarian teratocarcinoma-derived PA-1 cells, which 
endogenously express high levels of Lin28 
14,18,19, followed by RNA extraction and reverse transcription 
and quantitative real-time PCR (RT-qPCR).  Figure 1B illustrates the mRNA levels present in Lin28-
containing RNPs (red bars) compared to those identified using a rabbit pre-immune serum (blue bars; 
arbitrarily set as 1).  While the known Lin28 targets Hmga1 and Rps13 were enriched by ~5- and 30-
fold, respectively, in Lin28 IP vs. preimmune IP (2
nd and 3
rd columns from left, compare red bar with 
blue bar), the non-target beta-actin mRNA was not (1
st column from right).  Importantly, under the same 
conditions Bmp4 was also enriched, by nearly 7-fold (1
st column from left).  Significant enrichment of 
Bmp4, Hmga1, and Rps13 in Lin28 RNPs also was observed in the human EOC-derived line IGROV1 
(Fig. 1C, 1
st through 3
rd columns from left); this cell line previously has been shown to express  
 
endogenous Lin28, albeit at much lower levels when compared to PA-1 
14.  Together these observations 
support the hypothesis that BMP4 mRNA is physically associated with Lin28 in EOC-derived lines. 
 
Lin28 stimulates BMP4 expression at the posttranscriptional level   
Based on our previous studies showing that Lin28 enhances the translation of a number of its target 
mRNAs 
18-21 we proposed that Lin28 might also influence BMP4 expression in a similar fashion.  To 
test this hypothesis we first asked whether increasing Lin28 levels in EOC-derived cell lines that express 
low levels of endogenous Lin28 would lead to elevated BMP4 expression.  We transfected an epitope-
tagged Lin28 expression vector (FL-Lin28) 
19 into IGROV1 cells, followed by analysis of BMP4 
expression.  To facilitate measurement of BMP4 protein levels, we treated cells with the protein 
transport inhibitor GolgiPlug 
7 to block BMP4 secretion prior to total cellular protein extraction and 
immunoblotting analysis.  Under these conditions we observed an approximately 3-fold increase in 
BMP4 protein expression in cells transfected with FL-Lin28 compared to empty vector (Fig. 2A, top 
panel, top blot, compare lane 2 to lane 1).  The level of FL-Lin28 expression was ~15-fold higher than 
that of endogenous Lin28 (Fig. 2A, top panel, 2
nd blot from the top, compare the top to the bottom band 
in lane 2).  However, no change in BMP4 mRNA expression was observed in response to FL-Lin28 
expression (Fig. 2A, bottom panel, compare red bar with blue bar in the 1
st column from left).  Similar 
results were obtained when a second EOC-derived cell line, A2780, was tested.  A2780 cells express 
negligible levels of endogenous BMP4 and Lin28 (Fig. 2B, top panel, the 1
st and 2
nd blots from top in 
lane 1).  When FL-Lin28 was expressed exogenously (Fig. 2B, top panel, 2
nd blot from the top, lane 2), 
the level of BMP4 protein expression becomes readily detectable (Fig. 2B, top panel, top blot, lane 2), 
even though BMP4 mRNA levels are not significantly affected (Fig. 2B, bottom panel).  Next, we asked 
whether decreasing Lin28 expression in PA-1 cells that express robust levels of endogenous Lin28 
would result in reduced BMP4 production.  Thus, PA-1 cells were transfected with a control siRNA 
(siCon) or Lin28-specific siRNA (siLin28) 
18,19,21 and the effect on BMP4 expression was analyzed.  The  
 
level of Lin28 mRNA in siLin28-transfected cells was reduced by 98% compared to siCon-transfected 
cells (Fig. 2C, bottom panel, 1
st column from left, compare red bar with purple bar), with a concomitant 
~4-fold decrease in the Lin28 protein level (top panel, 2
nd blot from top, compare lane 2 to lane 1).  
Concomitant with this down-regulation of Lin28, the level of BMP4 protein expression was decreased 
by half  (Fig. 2C, top panel, top blot, compare lane 2 to lane 1), again without a significant change in 
BMP4 mRNA levels (bottom panel, middle column, compare red bar with purple bar).  Together, Lin28 
expression positively influences BMP4 at the protein level without affecting its mRNA, suggesting that 
BMP4 is likely regulated by Lin28 at the translational level. 
  To further investigate whether Lin28 might regulate BMP4 mRNA translation, we asked whether 
BMP4 mRNA contains the sequence element recognized by Lin28, thus enabling Lin28-dependent 
translational regulation.  We previously have reported that multiple Lin28 mRNA targets share a unique 
sequence and structural motif that is recognized by Lin28 and that enables Lin28-dependent stimulation 
of translation 
20.  This motif is characterized by a small “A” bulge flanked by two G:C base-pairs 
embedded in a complex secondary structure 
20.  Using the same bioinformatics approach combined with 
a heterologous reporter system we identified a 411-nt long Lin28-responsive element (LRE) in the 
coding region of BMP4 that possesses such properties (Fig. 2D, top panel, blue rectangle, and 
Supplementary Fig. S1).  When this LRE was inserted at the 3′-UTR of a well-characterized firefly 
luciferase (FFL) reporter gene 
18-21, it conveyed dose-dependent stimulation of translation by Lin28.  We 
used as a positive control a 129-nt LRE from Hmga1 
20 (Fig. 2D, bottom panel, yellow line), and found 
stimulatory effects similar to those observed using the 411-nt LRE region of Bmp4 (blue line); in 
comparison, neither the mutant Hmga1 element (Hmga1-53T, which contains an “A” to “T” single point 
mutation 
20, purple line) nor the parental FFL (red line) showed such a stimulatory effect.  Together, 
these results strongly suggest that BMP4 is regulated by Lin28 at the translational level via binding to a 
discrete LRE.  More detailed analyses will be needed to confirm this interpretation of these results. 
  
 
Co-expression of Lin28 and Oct4 is associated with unfavorable prognosis   
In light of the observation that Lin28 can promote BMP4 production via a canonical post-transcriptional 
regulatory mechanism, and also because BMP4 has been implicated in playing a critical role in ovarian 
CSC control as well as the pathogenesis of ovarian cancer 
7,22-26, we were motivated to determine, using 
immunohistochemical methods, whether expression of Lin28, together with Oct4, might be correlated 
with clinical outcome in EOC patients.  The rationale for including Oct4 was based on two previous 
observations.  First, co-expression of Lin28 and Oct4 in ovarian cancer cells is associated with increased 
tumor grade, and second, silencing the expression of both Lin28 and Oct4 results in synergistic 
inhibition of ovarian cancer cell growth and induction of apoptosis 
14.  Because BMP4 is a secreted 
protein, it is not possible to determine the precise compartment(s) (i.e., tumor cells, stroma, or both) 
from which this protein arises in ovarian tumor tissue samples using immunohistochemistry.  In contrast, 
Lin28 is a cytoplasmic protein that is expressed exclusively in the ovarian tumor cell compartment (see 
below).  The fact that BMP4 can be expressed from either compartment but Lin28 is only in tumor cells 
thus creates limitations that precluded us from performing co-localization studies with BMP4 without 
confounding interpretations.  Since expression of BMP2 (which binds to the same receptors of BMP4) 
has already been shown to be a prognostic factor in epithelial ovarian cancer 
25, and since BMP2 and 
BMP4 are likely functionally interchangeable 
7,13, we set out to study the potential relationship between 
Lin28/Oct4 expression and outcome in ovarian cancer.  Expression of Lin28 and Oct4 was examined 
using immunofluorescence microscopy using paraffin-embedded tumor (primary) samples from 343 
patients in the Yale Ovarian Cancer Cohort (Supplementary Table S1).  The Lin28 and Oct4 antibodies 
used in these studies have been well documented previously for specificity in detecting their respective 
antigens by immunoblot analysis 
14,18,19.  Lin28 and Oct4 protein levels were determined using the 
Automated Quantitative Analysis (AQUA) method 
27,28.  The distribution of both Lin28 and Oct4 scores 
is summarized in Figure 3A.  A heterogeneous pattern of expression across tumor samples was observed 
for both Lin28 and Oct4.  The AQUA scores of Lin28 ranged from 0 (undetectable values) to 4889.49,  
 
with mean and median values of 668.16 and 504.98, respectively.  In the case of Oct4, the AQUA scores 
ranged from 0 to 1063.58, with mean and median values of 110.22 and 87.88, respectively.  For both 
Lin28 and Oct4, most expression was detected in co-localization with cells expressing cytokeratin, 
which defines epithelially-derived tumor cells; staining was not detected in nearby stromal cells.  All 
Lin28/Oct4-positive histospots expressed Lin28/Oct4 homogeneously within the cytokeratin-staining 
compartment.  Figure 3B shows representative images of histospots expressing high levels of both Lin28 
and Oct4.  Consistent with the previously described localization of these two proteins in human ES and 
EC cells 
14,18, the expression patterns of Lin28 (panels I-IV) and Oct4 (Panels V-VIII) are predominantly 
cytoplasmic and nuclear, respectively. 
  Among the various clinico-/pathologic factors analyzed in the Yale Ovarian Cancer Cohort, age 
and stage were both predictably found to be independent risk factors for predicting progression free 
survival (PFS) and overall survival (OS) (Supplementary Table S2, Multivariate Model, p<0.001 for 
both PFS and OS by age, and p<0.001 for PFS by stage).  While neither Lin28 nor Oct4 expression 
alone showed significant association with survival, there was evidence of an interaction between Lin28 
and Oct4 that is significant in predicting both PFS and OS (Supplementary Table S2, p=0.038 for PFS, 
and 0.036 for OS).  To determine the nature of this interaction, multivariate analyses for PFS and OS 
were compared among patients with no, medium, or high Lin28 expression levels, and no, medium or 
high Oct4 expression levels.  As shown in Supplementary Table S3, odds ratios and hazard ratios 
suggested that patients with high levels of Lin28 and Oct4 co-expressed in their tumors (double high) 
had the least favorable PFS and OS, in comparison to other 8 groups (i.e., High Lin28/No Oct4, No 
Lin28/High Oct4, High Lin28/Medium Oct4, Medium Lin28/High Oct4, Medium Lin28/Medium Oct4, 
Medium Lin28/No Oct4, No Lin28/Medium Oct4, and No Lin28/No Oct4).  The survival curves 
illustrate that in the group of patients with high Lin28 expression, those with high Oct4 had worse 
survival than those with only high Lin28 (p=0.014) or high Oct4 (p=0.003) (Fig. 3C, left panel).  
Intriguingly, patients with no Lin28 and no Oct4 expression (double negative) also had worse survival  
 
than those with only high Lin28 (p=0.039) or high Oct4 (p=0.009), while no significant difference 
between the double negative and double high groups was found (p=0.075) (Fig. 3C, right panel).  
Importantly, these relationships remain significant after adjustment for other risk factors, including age, 
stage, grade, histology, bilateral involvement (BOI) and category.  Together, these results suggest that 




In this report, we demonstrate that the stem cell factor Lin28 not only physically interacts with BMP4 
mRNA (Fig. 1) but also stimulates BMP4 expression, we hypothesize, at the translational level (Fig. 2), 
in human EOC-derived cell lines.  We also have mapped a Lin28-responsive element (LRE) within the 
coding region of BMP4 mRNA that confers Lin28-dependent stimulation of translation using a 
heterologous reporter system (Fig. 2D).  Like other BMP family members, the activity of BMP4 as a 
secreted growth factor can be regulated at multiple levels including through the binding of soluble 
extracellular inhibitors, receptor oligomerization, endocytosis, and co-receptor association (reviewed in 
11).  In addition, epigenetic methylation of the promoter has been reported to affect BMP4 expression at 
the transcriptional level 
29.  Here we propose that Lin28 regulates BMP4 expression at the translational 
level, adding another layer of complexity to the regulation of BMP4 expression.   
  Both BMP4 and BMP2 have been shown to be critical in regulating the ovarian tumor 
microenvironment, and in so doing, tumor progression.  Shepherd et al 
22 reported that BMP4 secreted 
from ovarian cancer cells up-regulates the expression of the proto-oncogene inhibitor of differentiation 3 
(ID3) in an autocrine fashion, thereby driving tumorigenesis.  Autocrine BMP4 signaling also has been 
shown to induce epithelial-mesenchymal transition (EMT), and to increase adhesion, motility, and 
invasion of ovarian cancer cells 
23.  Similarly, up-regulation of BMP2 has been observed in ovarian 
cancer cells compared to normal ovarian surface epithelial cells, which are considered one potential  
 
progenitor cell type of epithelial ovarian cancer (EOC) 
24.  In addition, elevated expression of BMP2 in 
ovarian tumors has been associated with poor prognosis 
25.  The important role of BMPs in ovarian 
tumorigenesis is further supported by the observation that chordin, an extracellular BMP inhibitor, is 
downregulated in ovarian cancer cells compared to ovarian surface epithelial cells 
26.  Finally, a recent 
study has elegantly demonstrated that 1) ovarian carcinoma-associated mesenchymal stem cells (CA-
MSCs) are able to promote tumor growth more effectively than MSCs from healthy individuals in co-
culture experiments both in vitro and in a mouse model; and that 2) CA-MSCs secret significantly 
higher levels of BMP2 and BMP4, compared to control MSCs; 3) treatment of primary ovarian cancer 
cells or ovarian cancer-derived cell lines with BMP2 significantly increases the number of CSCs; and 4) 
in vitro and in vivo inhibition of BMP2/4 by Noggin (an extracellular BMP inhibitor) results in partial 
abrogation of CA-MSC promoted tumor growth 
7.  Collectively, these studies highlight the role of 
BMP2/4-mediated autocrine and paracrine signaling pathways in regulating the growth of human 
ovarian cancer cells. It is noteworthy that BMP4 also has been reported to induce differentiation and 
apoptosis of CSCs from glioma and colorectoral cancer 
30,31, in contrast to the situation where CA-MSC-
derived BMP2/4 promotes proliferation of CSCs in ovarian cancer 
7. This discrepancy provides further 
support for the notion that the physiological endpoints of BMP-mediated regulation are highly context-
dependent 
11,12. Indeed, distinct and cell-type-specific effects of BMP4 have been reported 
32. In this 
regard, high levels of Lin28 expression have been observed in extraembryonic endoderm, in addition to 
undifferentiated ES cells, suggesting a role for Lin28 in extraembryonic endoderm differentiation 
33. 
Importantly, BMP4 signaling is known to support differentiation of ES cells into both embryonic and 
extraembryonic lineages 
34,35.  We suspect that the interaction between Lin28 and BMP4 mRNA detected 
in extracts prepared from human ES cells (Fig. 1A and 
19) reflects the presence of a subpopulation of 
differentiating cells, rather than being a function of undifferentiated ES cells.    
  The regulation of BMP4 expression by Lin28, as well as our previous studies linking Lin28 and 
Oct4 to ovarian cancer cell growth stimulated us to examine potential clinical correlates of these  
 
observations.  In these studies we found no correlation between Lin28 or Oct4 expression alone and 
patient survival, consistent with one previous report demonstrating that high Lin28B, but not Lin28, is 
correlated with shorter PFS and OS in ovarian cancer patients 
36.  We also observed a statistically 
significant relationship between high Lin28 expression and high Oct4 expression (double high), and the 
risk of disease progression and death.  Specifically, patients in the double high cohort showed decreased 
PFS and OS in comparison to patients with other combinations of Lin28/Oct4 expression 
(Supplementary Table S3, and Fig. 3C, left panel).  This observation is consonant with our previous 
observation demonstrating that Lin28 and Oct4 are co-expressed in a sub-population of EOC cells in 
ovarian cancer-derived cell lines (as well as in a small cohort of tumor samples), and that simultaneous 
silencing of the expression of both these proteins synergistically inhibits ovarian cancer cell growth and 
survival 
14.  It is intriguing that patients in the double negative cohort also showed significantly poor 
prognosis (Fig. 3C, right panel), reminiscent of patients with ER/PR/HER2-triple negative breast cancer.  
It is likely that the double high and the double negative groups represent distinct underlying 
mechanisms.  Indeed, it has been reported that Lin28, and its paralog Lin28B, are mutually exclusively 
expressed in HER2-overexpressing and triple-negative breast cancer, respectively, and that the NF-κB 
transcription factor regulates Lin28B (but not Lin28)-mediated inflammatory circuit in the triple 
negative breast cancer 
37.  Future investigations will illuminate distinct mechanisms underlying the 
double high and the double negative ovarian tumors, which will be useful in customizing treatment for 
ovarian cancer patients.   
  We elected not to perform co-staining with BMP4 on ovarian tumor samples due to the challenges 
associated with data interpretation for this secreted protein.  However, its close relative BMP2, which 
acts via the same receptors as BMP4, and which often functions in parallel or perhaps even 
interchangeably with BMP4 
7,13, previously has been shown to independently be correlated with survival 
in ovarian cancer, despite the observation that the precise compartment(s) from which BMP2 is 
expressed in ovarian tumor samples cannot be determined using immunohistochemistry 
25.  Despite  
 
these limitations, we propose here that the results from our in vivo Lin28 and Oct4 tumor expression 
studies, combined with our in vitro results, provide potential new links revealing functional interactions 
among Lin28, Oct4, and BMP4 - links which may be relevant to ovarian cancer pathogenesis.  
  Specifically, we hypothesize that the Lin28/Oct4-double high EOC cells may represent a sub-
population of tumor cells that contributes critically to disease progression (Fig. 4).  These cells are 
capable of producing high levels of BMP4 partly under the influence of Lin28; this growth factor, in 
turn, stimulates CSC proliferation in a paracrine fashion.  In addition, BMPs derived from ovarian 
carcinoma-associated mesenchymal stem cells (CA-MSCs) also may stimulate CSC proliferation 
7.  One 
important question that remains is whether CSCs promote their own growth through autocrine signaling 
mechanisms, and if so, which growth factors are involved.  In this context, the possibility that BMP4 
may also regulate Lin 28 expression is an intriguing possibility that warrants further study. 
 
Materials and Methods 
Antibodies and DNA plasmids   
The antibodies specific for Lin28 (Abcam, ab46020), Oct4 (Santa Cruz, sc-5279), cytokeratin (DAKO, 
M351501-2), BMP4 (Abcam, ab39973), beta-tubulin (Abcam, ab6046), rabbit pre-immune serum 
(SouthernBiotech, 0040-01) and mouse pre-immune IgG (Chemicon PP54) were purchased.  The 
plasmids FL-Lin28, FFL, Hmga1-129, and Hmga1-53T were previously described 
18-21.  The Bmp4-411 
plasmid was made by cloning a PCR fragment containing the 411-nt BMP4 sequence (nt 845 to nt 1255 
relative to the transcriptional start site of human BMP4, NM_001202) at the NotI and XhoI sites of the 
parental FFL reporter gene.  A cDNA from PA-1 cells (as a template for the BMP4 gene) and a pair of 
forward (5’-AAGGAAAAAAGCGGCCGCtaacctcagcagcatccctga) and reverse (5’-
CCGCTCGAGccatcatggccaaaggtgacca) primers were used in the PCR reactions. 
 
Cell culture and transfection    
 
The culture and transfection of the human ovarian cancer-derived cell lines IGROV1 and A2870 and the 
human EC-derived PA-1 were carried out as previously described 
14,19. 
 
Immunoprecipitation, deep sequencing, and RT-qPCR   
These were carried out essentially as previously described 
18,19.  The PCR primers are listed below.  
Beta-actin forward: 5′-ATCAAGATCATTGCTCCTCCTGAG; beta-actin reverse: 5′-
CTGCTTGCTGATCCACATCTG; beta-tubulin forward: 5′-CGTGTTCGGCCAGAGTGGTGC; beta-
tubulin reverse: 5’-GGGTGAGGGCATGACGCTGAA; Bmp4 forward: 5′-
GTGGAGGAAGCTGACAACAA; Bmp4 reverse: 5′- GCCGGTTACAGAACCACACT; Lin28 
forward: 5′-CGGGCATCTGTAAGTGGTTC; Lin28 reverse: 5′-CAGACCCTTGGCTGACTTCT; 
Rps13 forward: 5’-CTCTCCTTTCGTTGCCTGAT; Rps13 reverse: 5′-
CCCTTCTTGGCCAGTTTGTA; Hmga1 forward: 5′- CAGCGAAGTGCCAACACCTAAG; Hmga1 
reverse: 5′- CCTTGGTTTCCTTCCTGGAGTT; FFL forward: 5′-GCTGGGCGTTAATCAGAGAG; 
FFL reverse: 5′-GTGTTCGTCTTCGTCCCAGT. 
 
Luciferase assays  
These were carried out as previously described 
18-20. 
 
Case selection and tissue annotation   
Three hundred and forty-three cases with ovarian pathology were identified from the Yale Pathology 
Archives to create a tissue microarray (TMA) in accordance with an Internal Review Board approved 
protocol.  All patients had received primary surgery for an adnexal tumor at the Yale University School 
of Medicine between 1980 and 2001.  Demographical, anthropomorphical, and clinicopathological 
parameters were collected from tumor registry data and through a detailed chart review of each case 
represented on the TMA.  Demographical and anthropomorphical parameters included: date of birth,  
 
race, gravidity, parity, hormone replacement therapy, body surface area in square meters, and smoking 
history.  Clinicopathological parameters included: date of diagnosis, clinical diagnosis (e.g., epithelial 
ovarian cancer [EOC], non-epithelial ovarian cancer, low malignant potential ovarian tumor [LMP], 
benign ovarian tumor, fallopian tube cancer, and other gynecological cancer or non-gynecological 
cancer with metastasis to the ovary), other cancer (i.e., synchronous or metachronous secondary 
cancers), serum CA125 value (Units/ml) at the time of diagnosis, International Federation of 
Gynecology and Obstetrics (FIGO) disease stage, tumor grade and histological subtype (i.e., serous, 
mucinous, endometrioid, clear cell, transitional, mixed, other), presence of ascites, number of lymph 
nodes positive for cancer, number of lymph nodes removed at surgery, maximum non-omental tumor 
size, residual tumor following surgery, bilateral ovarian involvement (BOI), date of surgery, date of first 
chemotherapy or radiation therapy, neoadjuvant therapy, type of adjuvant chemotherapy (e.g., 
doxorubicin with platinum, paclitaxel with platinum, and cyclophosphamide with platinum), date of 
recurrence, date last seen, and vital status. 
 
Tissue microarrays   
TMA construction was performed by the Yale University, Tissue Microarray Facility using paraffin-
embedded tissue blocks as previously described 
38.  Briefly, 0.6 mm diameter tissue cores of ovarian 
tumor tissue were spaced 0.8 mm apart on a recipient block using a precision instrument (Beecher, 
Silver Spring, MD), re-embedded in paraffin, and stored in a nitrogen chamber at room temperature.  
Duplicate cores of 17 ovarian tumors were included on the TMA as internal controls. 
 
Immunohistochemistry (IHC)   
Immunohistochemical staining of TMA slides was carried out essentially as previously described 
38.  
The anti-Lin28 (protein A sepharose affinity purified), anti-Oct4, and anti-cytokeratin antibodies were 
used at dilutions of 1:600, 1:200, and 1:100, respectively.  Protein A sepharose affinity purified rabbit  
 
and mouse pre-immune IgGs at the same IgG concentrations were used as negative controls for these 
antibodies, respectively. 
 
Automated quantitative analysis (AQUA)   
Automated quantitative analysis (AQUA) is a method that enables objective measurement of exact 
protein concentration within a defined tumor area or subcellular compartment 
28.  Using an Olympus 
AX-51 epifluorescent microscope and an algorithm for image collection 
27, a series of monochromatic 
high-resolution images were captured.  For each histospot an in- and out-of-focus image were acquired 
using the signals from the Lin28 (or Oct4)-Cy5 and cytokeratin-Alexa 488 channel, respectively.  Based 
on the cytokeratin signal a tumor mask representing epithelial tumor compartment and excluding 
stromal, lymphocytic and histocytic areas was created.  Only signal within the tumor mask was 
accounted for a positive score.  AQUA scores of each histospot were generated by dividing the signal 
intensity by the area of the tumor mask.   
 
Statistical analysis 
Exploratory data analysis:  Statistical analyses were performed using Stata version 12 (Stata Corp, 
College Station, Texas) or SAS version 9.3 (Statistical Analysis Software Institute, Cary, NC).  To 
define a cohort amenable to progression-free survival (PFS) and overall survival (OS) analysis, the 
descriptive statistics of all demographical, anthropomorphical, clinicopathological, and IHC parameters 
for all 404 cases represented in the TMA were first examined.  Parameters with a high percentage of 
missing data values and subgroups with a small numbers of cases were eliminated for further study as 
potential prognostic factors.  For example, race was eliminated as a potential prognosticator, because 
there were only 7 African American and 16 other, non-Caucasian patients among the cases.  In addition, 
EOC patients who had received neo-adjuvant therapy (n=14) were eliminated from analysis of PFS and 
OS, because of potential treatment effects on Lin28 and Oct4 tissue expression.  The assessment of  
 
potential prognostic factors, therefore, was reduced to a cohort of 343 patients with primary EOC 
(n=285), fallopian tube cancer (n=16), low malignant potential (LMP) ovarian tumors (n=5), non-
gynecologic (n=15) and other gynecologic (n=22) malignancies that had metastasized to the ovary.  To 
accommodate valid comparisons of univariate and multivariate regression models, this cohort was 
annotated with a final list of covariates that included: category of specimen (see Table S1), age at 
diagnosis, disease stage, tumor grade, tumor histology, Bilateral Involvement (BOI), and IHC labeling 
of Lin28 and Oct4.    
  Spearman’s rank correlation analysis was used to test for relationships between continuous 
covariates, and hence to reveal any potential confounders of a prognostic relationship.  In addition, mean 
IHC labeling of Lin28 and Oct4 was compared across categories of disease stage, tumor grade, tumor 
histology, BOI, and category of specimen to identify significant associations between these covariates 
by Wilcoxon rank-sum or Kruskal-Wallis tests. 
 
Survival analysis:  Progression-free survival was defined as the date of surgery until the date of first 
clinically recognizable evidence of local or distant recurrence.  Both left (n=70) and right (n=108) 
censoring was observed for PFS.  Patients were left censored if they died of EOC, but the date of disease 
recurrence was unknown.  Patients were right censored if they had no evidence of cancer recurrence at 
the last date seen alive.  To accommodate left censoring, a parametric accelerated failure time (AFT) 
regression model with a log-logistic distribution function was used to fit covariates for PFS 
39.  The log-
logistic distribution was chosen because it may be characterized by an exponentially decreasing survival 
probability function, which is conceptually plausible as recurrence of disease is most likely to occur 
soon after surgery among patients with more advanced stage disease and/or aggressive tumors.  In 
addition, the log-logistic AFT model facilitates the interpretation of transformed regression coefficeints 
as odds ratios.  Both univariate and multivariate AFT models of PFS were developed with the following 
covariates: patient age as a continuous variable, disease stage, tumor grade, tumor histology (serous vs.  
 
all other subtypes), BOI, and IHC labeling of Lin28 and Oct4. 
  Overall survival is defined as the date of surgery until the date of death or loss to follow-up.  Since 
only right censoring was observed for OS (n=201), multivariate Cox proportional hazard regression 
analysis 
40 was used to fit patient age as a continuous variable, disease stage, tumor grade, tumor 
histology (serous vs. all other subtypes), BOI, and IHC labeling of Lin28 and Oct4 to OS.  Analysis of 
Schoenfeld residuals along with univariate and global tests of the proportional hazards assumption using 
time-dependent covariates demonstrated that the hazard of dying is not proportional across stage I, II, 
III, and IV (data not shown).  Therefore, data were stratified by disease stage in multivariate Cox 
regression models for overall survival. 
  Exploratory multivariate AFT and stratified Cox regression modeling demonstrated the existence 
of a significant interaction between Lin28 and Oct4.  A backward stepwise elimination procedure was 
used to develop final multivariate AFT and Cox regression models for PFS and OS, respectively.  All 
statistical tests were two-sided and considered significant with a p-value <0.05. 
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Figure 1. Lin28 physically associates with BMP4 mRNA in Lin28-expressing cells.  (A) BMP4 
mRNA is enriched in Lin28-containing RNPs in human ES cells as revealed by IP and deep sequencing 
19.  RNA-Seq libraries were generated using RNAs captured by IP using anti-Lin28 or preimmune IgG.  
The libraries derived from Lin28 IP and preimmune IP samples were individually used for sequencing 
on an Illumina GAII platform.  Approximately 10 million 75-nt reads were obtained from each IP 
sample, and these sequences were uniquely aligned to a combined database of the human genome and 
splice junctions and these read counts were further analyzed using normalized values to identify 
transcripts that were significantly different between the Lin28 IP and preimmune IP samples.  The 
heights of the peaks indicate frequencies of the 75-nt sequence reads that match the particular exon 
regions of the genome marked as blue boxes at the bottom of the histograms.  (B, C) BMP4 mRNA was 
enriched in Lin28-containing RNPs in PA-1 (B) and IGROV1 (C) cells by IP, followed by RNA 
extraction and RT-qPCR analysis.  Relative abundance of the indicated mRNAs present in the anti-
Lin28 vs. preimmune IP complexes are shown as relative fold enrichment.  Error bars are mean ± SD 
(n=3). 
 
Figure 2.  Lin28 positively affects the expression of BMP4 at the protein level.  IGROV1 (A), 
A2780 (B), or PA-1 (C) cells were transfected with empty vector, FL-Lin28, siCon, or siLin28 as 
indicated.  Proteins and RNAs were extracted 48 h post-transfection and levels determined by Western 
blotting and RT-qPCR analysis, respectively.  Representative results of two independent experiments for 
each cell line are shown.  For protein analysis, beta-tubulin was used as a loading control.  Protein bands 
on Western gels were quantitated using the Bio-Rad Quantity One software.  For RNA analysis, beta-
tubulin mRNA was used for RNA level normalization, and beta-actin mRNA was used for non-target 
control for Lin28 effects.  The levels of BMP4, beta-actin, and Lin28 mRNAs from empty vector- or 
siCon-transfected cells were arbitrarily set as 1.  Error bars are mean ± SD.  (D) Reporter assays.  Top, a  
 
schematic drawing of human BMP4 transcript.  The red rectangle represents open reading frame, with 
the 411-nt LRE highlighted in blue.  Numbers are in nucleotides relative to the transcriptional start site 
of BMP4.  Outlined beneath is a firefly luciferase reporter construct (FFL) with the green box 
representing its coding region and the thin line representing 3′-UTR.  The position where the LRE was 
inserted is indicated.  Bottom, luciferase assay results.  The indicated constructs were each transfected 
into HEK293 cells that do not express endogenous Lin28, with increasing amounts of co-transfected FL-
Lin28.  Luciferase activities and FFL mRNA levels were measured 24 h post-transfection.  Relative 
luciferase activities were presented after normalization against FFL mRNA levels.  Luciferase activities 
from cells without FL-Lin28 transfected were arbitrarily set as 1.  Numbers are mean ± SD (n=3). 
 
Figure 3.  (A) Distributions of AQUA scores for Lin28 (left) and Oct4 (right) expressions in the Yale 
Ovarian Cancer Cohort. The range, mean and median values are indicated.  (B) Examples of 
immunofluorescence of human epithelial ovarian cancer samples using antibodies specific for Lin28 (I, 
in red), Oct4 (V, in red), or cytokeratin (II and VI, in green), respectively.  The Dapi stain (III and VII, 
in blue) indicates cell nuclear compartment.  III, merge of cytokeratin and Dapi; VII, merge of Oct4 and 
Dapi; IV, merge of cytokeratin and Lin28; VIII, merge of cytokeratin and Oct4.  Bar = 20 μm.  (C) 
Survival curves from a Cox proportional hazards regression analysis that included as covariates Lin28 
and Oct4, along with their interaction term.  Assessment of Lin28 and Oct4 expressions was performed 
in 3-fold redundancy.  
 
Figure 4. A model for Lin28/BMP4/Oct4-mediated regulation in ovarian tumor. 
 
Supplementary Figure S1. Predicted secondary structure of the 411-nt LRE from human BMP4 




Supplementary Table S1. Characteristics of Yale Ovarian Cancer Cohort. 
 
Supplementary Table S2.  Interactions between Lin28 and Oct4 in progression free survival (PFS) and 
overall survival (OS) of patients with ovarian tumors.  P-values are shown for null regression 
coefficients in univariate and multivariate Cox proportional hazards and accelerated failure time 
regression models for OS and PFS, respectively.  The multivariate Cox model for OS was stratified by 
disease stage.  The covariates (prognostic factors) used in the univariate and multivariate analyses 
included age at diagnosis, disease stage, tumor grade, tumor histology, bilateral involvement, category 
of specimen, and IHC labeling of Lin28 and Oct4.  The multivariate models suggest that an interaction 
between Lin28 and Oct4 significantly affects both PFS and OS. 
 
Supplementary Table S3. Co-expression of Lin28 and Oct4 at high levels associates with the least 
favorable prognosis.  Estimated odds ratios (OR), hazard ratios (HR), and 95% confidence intervals (CI) 
for patients with no, medium or high Lin28 labeling and no, medium or high Oct4 labeling compared to 
patients with no Lin28 and high Oct4 labeling (referent group) derived from a multivariate disease-
stage-stratified Cox model for OS and a log-logistic accelerated failure time model for PFS in patients 
with ovarian tumors.  High=90
th percentile of readable values of AQUA scores; Medium=the median 
(50
th percentile) of readable values of AQUA scores; No=no readable values of AQUA scores.  
 
 
 
 